An open study of botulinum-A toxin treatment of trigeminal neuralgia

Neurology. 2005 Oct 25;65(8):1306-8. doi: 10.1212/01.wnl.0000180940.98815.74.

Abstract

Thirteen subjects with trigeminal neuralgia were treated with botulinum-A neurotoxin (BoNT/A) in an open-label pilot study. After BoNT/A, visual analog scale score, surface area of pain, and therapeutic coefficient were reduced in all patients and for all branch trigeminal nerves studied. Therefore, BoNT/A is an efficient treatment. There were no major side effects. A placebo-controlled clinical trial is needed to confirm these findings.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Analgesics / therapeutic use
  • Anticonvulsants / therapeutic use
  • Blepharoptosis / chemically induced
  • Botulinum Toxins, Type A / administration & dosage*
  • Botulinum Toxins, Type A / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuropeptides / antagonists & inhibitors
  • Neuropeptides / metabolism
  • Neurotoxins / administration & dosage
  • Neurotoxins / adverse effects
  • Nociceptors / drug effects
  • Nociceptors / physiology
  • Pain Measurement / drug effects
  • Pain Threshold / drug effects
  • Pain Threshold / physiology
  • Pilot Projects
  • Sensory Receptor Cells / drug effects
  • Sensory Receptor Cells / physiology
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Treatment Outcome
  • Trigeminal Nerve / drug effects*
  • Trigeminal Nerve / physiopathology
  • Trigeminal Neuralgia / drug therapy*
  • Trigeminal Neuralgia / physiopathology

Substances

  • Analgesics
  • Anticonvulsants
  • Neuropeptides
  • Neurotoxins
  • Botulinum Toxins, Type A